PRF Technologies (PRFX) Net Income towards Common Stockholders Growth (3y) (2023 - 2024)
PRF Technologies (PRFX) Net Income towards Common Stockholders Growth (3y) (2023 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 51.28% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 2.94% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -70.54% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 4.50% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -7.75% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 66.11% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -17.90% |
| 10 | PRF Technologies | 706,290.59 | -3.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -59.30% |
| Mar 31, 2024 | -41.79% |
| Dec 31, 2023 | -37.11% |
| Sep 30, 2023 | -31.75% |
| Jun 30, 2023 | -37.13% |
| Mar 31, 2023 | -18.70% |